• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.

作者信息

Kotton Camille N, Kumar Deepali, Manuel Oriol, Chou Sunwen, Hayden Randall T, Danziger-Isakov Lara, Asberg Anders, Tedesco-Silva Helio, Humar Atul

机构信息

Transplant and Immunocompromised Host Service, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Division of Infectious Diseases, Department of Medicine, Ajmera Transplant Center and University of Toronto, Toronto, ON, Canada.

出版信息

Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.

DOI:10.1097/TP.0000000000005374
PMID:40200403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12180710/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/57dde24fc010/tpa-109-1066-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/ee0d4da9c9cc/tpa-109-1066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/499de2dc520a/tpa-109-1066-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/2a37ace0b982/tpa-109-1066-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/0586a90a2a36/tpa-109-1066-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/9696e45a9887/tpa-109-1066-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/57dde24fc010/tpa-109-1066-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/ee0d4da9c9cc/tpa-109-1066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/499de2dc520a/tpa-109-1066-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/2a37ace0b982/tpa-109-1066-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/0586a90a2a36/tpa-109-1066-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/9696e45a9887/tpa-109-1066-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e948/12180710/57dde24fc010/tpa-109-1066-g006.jpg

相似文献

1
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.《实体器官移植中巨细胞病毒管理的第四届国际共识指南》
Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.
2
WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.撤回：实体器官移植中使用抗病毒药物进行巨细胞病毒预防。
Cochrane Database Syst Rev. 2007 Jul 18;1998(4):CD001320. doi: 10.1002/14651858.CD001320.pub2.
3
Patient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study.德国实体器官和造血干细胞移植后巨细胞病毒血症及疾病的患者数量和治疗模式：德尔菲共识研究结果
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03210-x.
4
Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.实体器官移植中使用抗病毒药物进行巨细胞病毒预防
Cochrane Database Syst Rev. 2000(2):CD001320. doi: 10.1002/14651858.CD001320.
5
Standardizing Care and Management of Cytomegalovirus Infections in Solid Organ Transplant Recipients: Highlights From the Fourth Consensus Guidelines.实体器官移植受者巨细胞病毒感染的护理与管理标准化：第四次共识指南要点
Transplantation. 2025 Jul 1;109(7):1111-1112. doi: 10.1097/TP.0000000000005380. Epub 2025 Apr 9.
6
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.预防实体器官移植受者巨细胞病毒病和早期死亡的抗病毒药物：随机对照试验的系统评价
Lancet. 2005;365(9477):2105-15. doi: 10.1016/S0140-6736(05)66553-1.
7
[Infectious disease assessment in solid organ transplant candidates].[实体器官移植候选者的传染病评估]
Enferm Infecc Microbiol Clin. 2002 Nov;20(9):448-61. doi: 10.1016/s0213-005x(02)72841-3.
8
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.固体器官移植受者的共生元、益生元和益生菌。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
9
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.骨关节炎研究学会国际联盟（OARSI）髋膝关节骨关节炎管理建议，第二部分：OARSI循证专家共识指南
Osteoarthritis Cartilage. 2008 Feb;16(2):137-62. doi: 10.1016/j.joca.2007.12.013.
10
Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.结直肠源性腹膜转移瘤治疗的推荐意见与共识：对国内及国际指南的系统评价
Colorectal Dis. 2017 Mar;19(3):224-236. doi: 10.1111/codi.13593.

引用本文的文献

1
Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023.实体器官移植受者巨细胞病毒管理的进展：来自2023年欧洲器官移植学会巨细胞病毒研讨会的见解
Transpl Int. 2025 Aug 22;38:14195. doi: 10.3389/ti.2025.14195. eCollection 2025.
2
Utility of the ELISpot Test to Predict the Risk of Developing BK Polyomavirus Nephropathy in Kidney Recipients, a Multicenter Study.ELISpot检测在预测肾移植受者发生BK多瘤病毒肾病风险中的应用：一项多中心研究
Vaccines (Basel). 2025 Jul 28;13(8):796. doi: 10.3390/vaccines13080796.
3
Should Systematic HSV Serological Screening of Donors Be Implemented to Manage Mismatched HSV D+/R- Liver Transplants?

本文引用的文献

1
Survey of Post-Prophylaxis Delayed-Onset Cytomegalovirus Management Strategies Among Transplant Providers.移植医护人员在后预防时期巨细胞病毒管理策略的调查。
Clin Transplant. 2024 Nov;38(11):e70015. doi: 10.1111/ctr.70015.
2
Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database (CHARMD).全面疱疹病毒抗病毒药物耐药性突变数据库（CHARMD）。
Antiviral Res. 2024 Nov;231:106016. doi: 10.1016/j.antiviral.2024.106016. Epub 2024 Sep 28.
3
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.
是否应实施供体单纯疱疹病毒（HSV）系统血清学筛查以管理不匹配的HSV D+/R-肝移植？
Transpl Int. 2025 Jul 21;38:14835. doi: 10.3389/ti.2025.14835. eCollection 2025.
4
Applications of CRISPR-Cas-Based Genome Editing Approaches Against Human Cytomegalovirus Infection.基于CRISPR-Cas的基因组编辑方法在抗人巨细胞病毒感染中的应用。
Biomedicines. 2025 Jun 30;13(7):1590. doi: 10.3390/biomedicines13071590.
5
Debates in Management and Treatment of CMV in Pediatric Solid Organ Transplant Recipients: A Case-Based Discussion.小儿实体器官移植受者巨细胞病毒管理与治疗的辩论：基于病例的讨论
Pediatr Transplant. 2025 Aug;29(5):e70135. doi: 10.1111/petr.70135.
6
Case Report: Donor-derived herpes simplex virus type 1 hepatitis in a kidney transplant recipient with fatal outcome.病例报告：肾移植受者发生供体来源的1型单纯疱疹病毒性肝炎并导致死亡。
Front Transplant. 2025 May 13;4:1591855. doi: 10.3389/frtra.2025.1591855. eCollection 2025.
在一项治疗巨细胞病毒感染的随机3期临床试验中，马立巴韦与更昔洛韦耐药性的比较出现情况
J Infect Dis. 2025 Mar 17;231(3):e470-e477. doi: 10.1093/infdis/jiae469.
4
Cell-mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multicenter Single-arm Prospective Study.细胞介导免疫指导器官移植受者巨细胞病毒感染的一级预防：一项多中心单臂前瞻性研究
Transplantation. 2025 Mar 1;109(3):527-535. doi: 10.1097/TP.0000000000005173. Epub 2024 Aug 20.
5
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.移植相关病毒感染论坛：用于临床试验的移植患者中巨细胞病毒（CMV）感染和疾病（包括耐药和难治性 CMV）的共识定义：2024 年更新。
Clin Infect Dis. 2024 Sep 26;79(3):787-794. doi: 10.1093/cid/ciae321.
6
Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation.细胞免疫对巨细胞病毒的作用及肾移植后感染的风险。
Front Immunol. 2024 Jun 28;15:1414830. doi: 10.3389/fimmu.2024.1414830. eCollection 2024.
7
Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients.使用乐韦莫韦进行肺移植受者巨细胞病毒原发性预防。
Transpl Infect Dis. 2024 Oct;26(5):e14337. doi: 10.1111/tid.14337. Epub 2024 Jul 9.
8
Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients.小儿实体器官移植受者中缬更昔洛韦预防的多中心分析
Open Forum Infect Dis. 2024 Jul 1;11(7):ofae353. doi: 10.1093/ofid/ofae353. eCollection 2024 Jul.
9
The Conversion From Mycophenolic Acid to Mammalian Target of Rapamycin Inhibitor Reduces the Incidence of Cytomegalovirus Replication in Belatacept-Treated Kidney-Transplant Recipients.从霉酚酸转换为雷帕霉素哺乳动物靶点抑制剂可降低接受贝拉西普治疗的肾移植受者中巨细胞病毒复制的发生率。
Kidney Int Rep. 2024 Mar 1;9(6):1912-1915. doi: 10.1016/j.ekir.2024.02.1433. eCollection 2024 Jun.
10
Virus-specific T cell efficacy after solid organ transplantation: More questions than answers.实体器官移植后病毒特异性T细胞的功效：问题多于答案。
Am J Transplant. 2024 Sep;24(9):1532-1533. doi: 10.1016/j.ajt.2024.05.021. Epub 2024 Jun 13.